Related Experiment Video

Updated: May 24, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Novel approaches for reducing free light chains in patients with myeloma kidney

Colin A Hutchison1, Joan Bladé, Paul Cockwell

  • 1Renal Institute of Birmingham, University Hospital Birmingham and University of Birmingham, Birmingham, UK. c.a.hutchison@ bham.ac.uk

Nature Reviews. Nephrology
|February 22, 2012
PubMed

Insights

Reducing monoclonal free light chains (FLCs) early in multiple myeloma kidney disease improves kidney recovery and patient survival. Further research is needed to optimize FLC depletion strategies for better outcomes.

Area of Science:

  • Nephrology
  • Oncology
  • Pathology

Background:

  • Myeloma kidney, a tubulointerstitial disease, causes 80-90% of severe acute kidney injury in multiple myeloma patients.
  • Without prompt intervention, irreversible damage like interstitial fibrosis and tubular atrophy progresses.
  • Recent research highlights the importance of reducing pathogenic monoclonal free light chains (FLCs).

Purpose of the Study:

  • To review the current knowledge on managing myeloma kidney.
  • To emphasize the significance of early and sustained reduction of FLCs.
  • To highlight the formation of the International Kidney and Monoclonal Gammopathy Research Group for a coordinated approach.

Main Methods:

  • Review of existing research and clinical data on myeloma kidney.
  • Analysis of the impact of FLC reduction on renal recovery and patient survival.
  • Discussion of the challenges and future directions in FLC depletion.

Main Results:

  • Early, sustained reduction in serum FLCs correlates with improved renal recovery rates.
  • Enhanced renal function in early stages is linked to better patient survival.
  • The optimal methods for achieving FLC depletion require further investigation.

Conclusions:

  • Early reduction of FLCs should be the standard of care for myeloma kidney.
  • Further research is essential to determine the best strategies for FLC depletion.
  • A cross-disciplinary approach is crucial for advancing research and management of myeloma kidney.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...